Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel Plus Imatinib in Metastatic Breast Cancer
NCT00193180Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- May 2005
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in breast cancer, sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate at 18 months. Started May 2005; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00193180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193180.